
Zoetis (ZTS) Stock Forecast & Price Target
Zoetis (ZTS) Analyst Ratings
Bulls say
Zoetis is poised for continued growth, with an estimated revenue of $555 million from Apoquel, reflecting a 4% year-over-year increase, and substantial contributions from Librela, projecting a significant 132% growth in dog sales and positively impacting overall market dynamics. The firm benefits from its strong market position, leveraging incremental sales growth strategies for both companion and production animal segments, which could enhance operational revenue growth by 20-30 basis points following portfolio adjustments. Furthermore, the upcoming financial estimates suggest robust operational revenue growth of approximately 9.0% for 1Q24, underscoring an optimistic trajectory that exceeds consensus expectations.
Bears say
Zoetis's financial outlook is negatively impacted by a projected deceleration in operational growth rates and earnings per share (EPS), with estimates for 2025 revised down to approximately 5-6%, below Wall Street consensus of 7.1%. The company faces multiple headwinds, including unfavorable foreign exchange impacts and challenges in revenue growth from its key product, Apoquel, suggesting a downward bias in future estimates. Additionally, increasing competition from generics and macroeconomic uncertainties pose significant risks that could further diminish market share and pricing power, contributing to a cautious long-term outlook for Zoetis's stock performance.
This aggregate rating is based on analysts' research of Zoetis and is not a guaranteed prediction by Public.com or investment advice.
Zoetis (ZTS) Analyst Forecast & Price Prediction
Start investing in Zoetis (ZTS)
Order type
Buy in
Order amount
Est. shares
0 shares